Press Releases

Date	Title
September 29, 2015	Oncobiologics Secures Financing from Sabby Management, LLC Oncobiologics Secures Financing from Sabby Management, LLC to Advance BioSymphony TM Platform and Monoclonal Antibody Biosimilars Pipeline Cranbury, NJ – Sept. 29, 2015 — Oncobiologics, Inc. (“Oncobiologics”) announced that it closed an additional round of financing with Sabby Management, LLC.
September 16, 2015	Oncobiologics Appoints Lawrence A. Kenyon as Chief Financial Officer Oncobiologics, Inc. announced the appointment of Lawrence A. Kenyon as its Chief Financial Officer (CFO), effective September 15, 2015. Mr. Kenyon is an accomplished executive with extensive experience managing the financial and business operations of emerging and established private and public
July 27, 2015	Oncobiologics Secures $31 Million Financing Cranbury, NJ – July 27, 2015 — Oncobiologics, Inc.,announced the closing of a $31 million financing. Proceeds will be used to support continued development and expansion of the company’s proprietary BioSymphony™ biosimilar platform and advancement of its preclinical and clinical programs.
July 2, 2015	Noted Immunology Expert Joins Oncobiologics as Chief Medical Officer June 2015 - Cranbury, New Jersey — Kenneth Bahrt, MD, FACR has joined Oncobiologics as its Chief Medical Officer. A recognized expert in immunology, he brings over 30 years of clinical and pharmaceutical industry experience in both small molecule and protein therapeutics. Oncobiologics Founder
May 4, 2015	Oncobiologics opens commercial launch manufacturing facility Oncobiologics, Inc.,a biotherapeutics company focused on developing and commercializing monoclonal antibody (mAb) biosimilars,has completed the construction of its GMP commercial launch manufacturing facility at its headquarters in Cranbury, New Jersey.
April 15, 2015	Oncobiologics announces completion of clinical dosing for bevacizumab (Avastin® biosimilar) candidate Oncobiologics, Inc.,a biotherapeutics company focused on developing and commercializing biosimilars, today announced that clinical development for ONS-1045, an Avastin®/bevacizumab biosimilar candidate, is underway with dosing completed in its pivotal pharmacokinetic (PK) study. This study is
February 12, 2015	ONS-3010 (Humira®/adalimumab biosimilar) meets primary endpoints in first clinical study Cranbury, NJ – February 12, 2015 — Oncobiologics, Inc.,a biotherapeutics company focused on developing and commercializing biosimilars,announced today that ONS-3010, its adalimumab (Humira®) biosimilar candidate met the primary endpoints in its first clinical study.
October 7, 2014	Oncobiologics Appoints Dr. Todd C. Brady to its Board of Directors Cranbury, NJ -- October 7, 2014 – Oncobiologics, Inc., a biotherapeutics company focused on developing and commercializing complex biosimilars, announced the appointment of Aldeyra Therapeutics CEO Todd C. Brady, M.D., Ph.D, to its Board of Directors.
July 16, 2014	Strides Arcolab makes strategic investment in Oncobiologics July 16, 2014: Cranbury, NJ Strides Arcolab and Oncobiologics, Inc., today announced that Strides has made a series of strategic investments in Oncobiologics, Inc, a privately held New Jersey biopharmaceutical firm developing a pipeline of biosimilars and next generation biotherapeutics.
June 26, 2014	Liomont and Oncobiologics partner to launch Biosimilars in Mexico Cranbury, NJ – June 26, 2014 — Oncobiologics, Inc. and Laboratorios Liomont S.A. de C.V. announced today a strategic partnership for the development, manufacture and commercialization of biosimilar monoclonal antibody products for the Mexican market. The scope of the agreement includes exclusive